2024/08/15 AD Others
Microorganisms, too embarrassed to ask others about!(Part 15)
Part 3 Sterilization 3. Microoraganisms will never be eliminated even after a number of extermination procedures "In the previous article, I clea
2024/04/03 AD Others
Microorganisms, too embarrassed to ask others about!(Part 14)
In this part, I would like to describe sterilization. Sterilization is employed widely in the drug product and medical device industries. You may have
2024/02/26 AD Others
Microorganisms、too embarrassed to ask others about!(Part 13)
5.5 Raw Materials, and Labeling and Packaging Materials <Notes> 1. Since most raw materials and materials are purchased from outside sources, t
2024/01/12 AD Others
Microorganisms、too embarrassed to ask others about!(Part 12)
5.1 What Microorganisms Like/Dislike In principle, every kind of microorganisms from bacteria, fungi to viruses are the subjects for microbiological c
2023/11/22 AD Others
Microorganisms、too embarrassed to ask others about!(Part 11)
4.1 Extermination with Heat We have two major approaches to exterminate microorganisms with heat: heating under the condition where water exists (mois
2023/08/10 AD Others
Microorganisms、too embarrassed to ask others about!(Part 10)
3. The Reasons Why Microbiological Control is Necessary As I wrote in one of my earlier articles, microorganisms exist everywhere. They should exist i
2025/10/23 AD Quality System
What the Revised GMP Ministerial Ordinance changed.
On Establishing the Required Structure for a Modern QA Department [Part 2]
2025/08/06 AD Quality System
Fact from 2,500 of FDA Form 483s
Data Integrity Issue Trend on FDA Inspections
2025/09/03 AD Quality System
On Establishing the Required Structure for a Modern QA Department [Part 1]
2025/05/15 AD
Deficiencies in multi-purpose manufacturing site
PMDA ORANGE LETTER_2025.01
2025/11/14 AD
Deficiency in Sterility Assurance by Sterilization Validation
PMDA ORANGE LETTER_2025.08
2025/08/05 AD
Problems Behind Discrepancies with product authorization requirements
PMDA ORANGE LETTER_2025.05
2025/07/15 AD
PMDA ORANGE LETTER_2025.03
2025/01/23 AD
Findings related to discrepancies with approved dossier and fake record
PMDA ORANGE LETTER_2024.10
AD
医薬品の技術移転のポイント【第3回】
Morio Wakisaka
Ryoichi Tanaka
You will be navigated to the CM Plus company website.
CM Plus Group Website